Quick Answer
Theravance Biopharma, Inc. reported Net Income Loss of $105.90 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +287.7% in Net Income Loss from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Theravance Biopharma, Inc.'s Net Income Loss has grown by 1,206.0%.
- Historical annual values: Fiscal year 2025: $105.90 million | Fiscal year 2024: -$56.42 million | Fiscal year 2023: -$55.19 million | Fiscal year 2022: $872.13 million | Fiscal year 2021: -$199.43 million | Fiscal year 2020: -$278.02 million | Fiscal year 2019: -$236.46 million | Fiscal year 2018: -$215.52 million | Fiscal year 2017: -$285.41 million | Fiscal year 2016: -$190.67 million | Fiscal year 2015: -$182.22 million | Fiscal year 2014: -$237.04 million | Fiscal year 2013: -$156.28 million | Fiscal year 2012: -$9.58 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: